Table 2.
Demographic and clinical characteristics of the study participants classified according to whether they progressed to Alzheimer’s disease.
| Stable aMCIa | aMCI-ADb | p-value | |
|---|---|---|---|
| Numbers | 900 | 284 | |
| Age, years | 72.8 ± 5.5 (60–85) | 75.6 ± 5.6 (60–85) | < 0.001 |
| Female:Male | 555: 345 | 176: 108 | 0.944 |
| Education, years | 8.7 ± 4.4 (0–23) | 7.7 ± 4.7 (0–18) | 0.002 |
| MMSE | 23.1 ± 3.2 (9–30) | 21.7 ± 3.7 (10–30) | < 0.001 |
| SGDS | 6.0 ± 3.4 (0–15) | 6.5 ± 3.8 (0–15) | 0.038 |
| Family history of dementia | 100 (11.1) | 41 (14.4) | 0.141 |
| Follow-upc, years | 3.2 ± 2.0 (0.9–9.4) | 2.7 ± 1.8 (0.9–9.3) | < 0.001 |
Variables are presented mean ± standard deviation (range) or frequency (%). aMCI, amnestic mild cognitive impairment; AD, Alzheimer’s disease; MMSE, mini-mental state examination; SGDS, short form of geriatric depression scale.aaMCI participants who did not progress to AD dementia or other dementias.baMCI participants who progressed to AD.cTime from baseline to last assessment for the stable aMCI group and conversion time from aMCI to AD for the aMCI-AD group.